The Novogene Europe single-cell RNA sequencing expansion strengthens the company’s UK multiomics capabilities, giving academic, biotechnology, and pharmaceutical researchers greater access to advanced transcriptomics services closer to their laboratories.
The Novogene Europe single-cell RNA sequencing expansion marks another milestone in the company’s strategy to strengthen its multiomics research infrastructure across Europe. Novogene Europe has announced the expansion of its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, reinforcing the facility’s role as a regional hub for advanced genomics and bioinformatics services.
The latest investment enables researchers across the United Kingdom to access high-quality single-cell sequencing workflows without relying on overseas laboratory infrastructure. By bringing advanced transcriptomics services closer to customers, Novogene Europe aims to improve project turnaround times while providing localized scientific support for increasingly complex research programs.
The expansion follows the recent introduction of the company’s untargeted metabolomics service at the Cambridge Omics Centre, reflecting a broader strategy to establish the facility as a comprehensive multiomics research destination. Together, these investments demonstrate Novogene Europe’s continued focus on building integrated research capabilities that support life sciences organizations throughout every stage of biological discovery.
Single-cell sequencing has rapidly become one of the most influential technologies in modern biomedical research. Unlike conventional bulk sequencing methods that measure average gene activity across thousands or millions of cells, single-cell RNA sequencing enables scientists to examine gene expression at the level of individual cells. This higher level of resolution allows researchers to identify subtle biological differences that may otherwise remain hidden, particularly within highly complex tissues and disease environments.
As pharmaceutical companies and research institutions continue investing in precision medicine, demand for technologies capable of revealing cellular diversity has increased significantly. The expansion of Novogene Europe single-cell RNA sequencing services is intended to address this growing demand by combining laboratory expertise, high-throughput sequencing infrastructure, and advanced bioinformatics within a single research workflow.
Novogene Europe Single-Cell RNA Sequencing Strengthens UK’s Multiomics Research Infrastructure
The newly expanded Novogene Europe single-cell RNA sequencing service is built around the widely adopted 10x Genomics Chromium platform, enabling researchers to generate high-resolution transcriptomic data from both individual cells and isolated nuclei. The initial service offering focuses on 3′ gene expression analysis supported by GEM-X chemistry, providing researchers with a reliable approach for investigating complex biological systems across multiple therapeutic areas.
The service extends well beyond sequencing alone. Researchers receive end-to-end project support that includes sample preparation, quality assessment, library construction, high-throughput Illumina sequencing, and comprehensive bioinformatics analysis. By integrating these components into a single workflow, Novogene Europe aims to reduce technical complexity while helping research teams interpret increasingly large genomic datasets.
The applications of single-cell RNA sequencing continue to expand across biomedical science. In oncology, researchers use the technology to study tumor heterogeneity and identify treatment-resistant cancer cell populations that may influence disease progression. In immunology, it enables detailed characterization of immune cell behavior, supporting the development of more targeted immunotherapies and vaccine research.
The technology is equally valuable in neuroscience, where scientists investigate diverse neuronal cell populations and their roles in neurological disorders. Developmental biology researchers use single-cell sequencing to understand cellular differentiation during tissue formation, while stem cell scientists apply the approach to evaluate cell identity and therapeutic potential.
Biopharmaceutical companies are also increasingly incorporating single-cell transcriptomics into biomarker discovery programs and drug development pipelines. Understanding cellular responses at individual cell resolution can provide valuable insights into treatment mechanisms, improve target identification, and support patient stratification strategies during clinical development.
Beyond its new Cambridge capability, Novogene Europe continues to offer an expanded portfolio of advanced single-cell services, including 5′ gene expression analysis and immune profiling that incorporates T-cell receptor and B-cell receptor sequencing. Together, these technologies provide researchers with a broader toolkit for investigating immune function and disease biology.
Cambridge Omics Centre Becomes Strategic Hub for Advanced Life Sciences Research
The expansion of Novogene Europe single-cell RNA sequencing reflects a wider transformation taking place within the life sciences services industry. As research projects increasingly combine genomics, transcriptomics, metabolomics, proteomics, and computational biology, demand is growing for integrated service providers capable of supporting multiomics studies under a unified scientific framework.
Novogene Europe’s investment in the Cambridge Omics Centre positions the facility to meet this evolving market need. Located within one of Europe’s leading biotechnology clusters, the centre is expected to play an increasingly important role in supporting universities, research institutes, biotechnology companies, pharmaceutical organizations, and clinical research groups seeking access to advanced molecular analysis technologies.
The company’s decision to strengthen local capabilities also reflects a broader industry trend toward regional scientific infrastructure. By expanding laboratory operations closer to customers, research service providers can improve collaboration, reduce logistical complexity, and provide more responsive scientific consultation throughout project execution.
The announcement coincides with Novogene’s fifteenth anniversary, highlighting the company’s continued investment in expanding its global research network while strengthening regional operations across Europe. Rather than relying solely on centralized laboratory capacity, the company is building specialized centres capable of supporting local scientific communities with advanced sequencing technologies and dedicated bioinformatics expertise.
Commenting on the expansion, Tingting Zhou, Vice President of Novogene Europe, noted that single-cell sequencing has become an essential tool for understanding complex biological systems at a level that conventional bulk sequencing approaches cannot achieve. She explained that expanding these capabilities within the Cambridge Omics Centre strengthens support for researchers working across disciplines including oncology, immunology, neuroscience, developmental biology, and translational medicine.
From a business perspective, the latest expansion reinforces Novogene Europe’s strategy of becoming a comprehensive multiomics research partner rather than a provider of individual laboratory services. As research organizations increasingly seek integrated analytical solutions capable of generating multiple layers of biological data, companies offering broad scientific capabilities are likely to become increasingly important collaborators throughout the research and development process.
The expansion of Novogene Europe single-cell RNA sequencing therefore represents more than an increase in laboratory capacity. It demonstrates the company’s commitment to supporting the next generation of biomedical research through localized expertise, advanced sequencing technologies, and integrated multiomics services that help researchers translate complex biological data into meaningful scientific discoveries.
